A Study of Thioctic Acid and Deprenyl in HIV-Infected Patients With Dementia

Phase 2

Completed

• Conditions: Cognitive Disorders; HIV Infections

• Registration Number: NCT00002154
• Lead Sponsor: The Dana Foundation

Brief Summary

The purpose of this study is to see if it is safe and effective to give thioctic acid and deprenyl (selegiline hydrochloride), alone or in combination, to HIV-infected patients who have mild to moderate dementia (a decline in their mental abilities).

Detailed Description

Patients are randomized to receive thioctic acid alone, deprenyl alone, thioctic acid/deprenyl, or placebo alone for 10 weeks, after which all patients may receive active drug on an open-label basis. Patients must have seven clinic visits.

Study Timeline

• Status Verified: 1996-03
• Study First Submitted: 1999-11-02
• Study First Submitted QC: 2001-08-30
• Study First Posted: 2001-08-31
• Last Update Submitted: 2005-06-23
• Last Update Posted: 2005-06-24

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 32

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: Not specified

Trial Locations

Locations (3)

Univ of Rochester Med Ctr; 🇺🇸 Rochester, New York, United States

Johns Hopkins Hosp; 🇺🇸 Baltimore, Maryland, United States

Columbia Univ; 🇺🇸 New York, New York, United States